2023
Disparities in stage at diagnosis among breast cancer molecular subtypes in China
Zeng H, Wu S, Ma F, Ji J, Lu L, Ran X, Shi J, Li D, An L, Zheng R, Zhang S, Chen W, Wei W, He Y, He J. Disparities in stage at diagnosis among breast cancer molecular subtypes in China. Cancer Medicine 2023, 12: 10865-10876. PMID: 36951474, PMCID: PMC10225199, DOI: 10.1002/cam4.5792.Peer-Reviewed Original ResearchConceptsBody mass indexBreast cancerMolecular subtypesMass indexFamily historyFirst primary invasive breast cancerFirst primary breast cancerPrimary invasive breast cancerHuman epidermal growth factor receptor 2Early-stage breast cancerEpidermal growth factor receptor 2Triple-negative breast cancerBreast cancer molecular subtypesEnd Results (SEER) databaseBreast cancer treatment strategiesGrowth factor receptor 2Primary breast cancerInvasive breast cancerOverweight/obeseStage breast cancerBreast cancer patientsBreast cancer casesCancer molecular subtypesFactor receptor 2Cancer treatment strategies
2018
Epithelial membrane protein 2: a novel biomarker for circulating tumor cell recovery in breast cancer
Chen Q, Yao L, Burner D, Minev B, Lu L, Wang M, Ma W. Epithelial membrane protein 2: a novel biomarker for circulating tumor cell recovery in breast cancer. Clinical And Translational Oncology 2018, 21: 433-442. PMID: 30218306, DOI: 10.1007/s12094-018-1941-1.Peer-Reviewed Original ResearchConceptsEpithelial membrane protein-2MDA-MB-231 cellsBreast cancerBreast cancer cellsNovel biomarkersMCF7 cellsCancer cellsAnti-pan cytokeratinPrimary breast cancerBreast cancer patientsMesenchymal transition eventsPatient blood samplesTumor cell recoveryFlow cytometric assayCTC countCancer patientsHealthy donorsBlood samplesMembrane protein 2Cytometric assayTumor cellsEMP2 expressionCancerCell spikingBiomarkers
2012
Association of large noncoding RNA HOTAIR expression and its downstream intergenic CpG island methylation with survival in breast cancer
Lu L, Zhu G, Zhang C, Deng Q, Katsaros D, Mayne ST, Risch HA, Mu L, Canuto EM, Gregori G, Benedetto C, Yu H. Association of large noncoding RNA HOTAIR expression and its downstream intergenic CpG island methylation with survival in breast cancer. Breast Cancer Research And Treatment 2012, 136: 875-883. PMID: 23124417, DOI: 10.1007/s10549-012-2314-z.Peer-Reviewed Original ResearchConceptsPrimary breast cancerBreast cancerHOTAIR expressionPathologic featuresCox proportional hazards regression modelProportional hazards regression modelsLow HOTAIR expressionUnfavorable disease characteristicsHazards regression modelsIndependent prognostic markerHigh HOTAIR expressionBreast cancer progressionQuantitative RT-PCRPatient survivalDisease characteristicsMethylation-specific PCRPrognostic markerLower riskSignificant associationRNA HOTAIRCancerCancer progressionBiologic relevanceRT-PCRDNA methylationFavorable outcome associated with an IGF-1 ligand signature in breast cancer
Mu L, Tuck D, Katsaros D, Lu L, Schulz V, Perincheri S, Menato G, Scarampi L, Harris L, Yu H. Favorable outcome associated with an IGF-1 ligand signature in breast cancer. Breast Cancer Research And Treatment 2012, 133: 321-331. PMID: 22297468, DOI: 10.1007/s10549-012-1952-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularCohort StudiesDisease-Free SurvivalFemaleGene ExpressionGene Expression ProfilingGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansInsulin-Like Growth Factor Binding ProteinsInsulin-Like Growth Factor IKaplan-Meier EstimateLigandsMiddle AgedMultivariate AnalysisNeoplasm Recurrence, LocalOligonucleotide Array Sequence AnalysisPrognosisReceptor, IGF Type 1Young AdultConceptsIGF-1 ligandBreast cancerFavorable outcomeInsulin-like growth factor (IGF) axisActivation signaturePrimary breast cancerGrowth factor axisPredictors of responseHuman breast cancerPathway analysisUpregulation of pathwaysBetter prognosisIGF axisPrognostic valueReceptor levelsLevels of mRNAFactor axisIGF ligandsIngenuity softwarePathway activation scoresCancerLigand levelsActivation scoresHigh groupProliferation pathways
2008
High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1
Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R, Mu L, Yu H. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1. Breast Cancer Research And Treatment 2008, 117: 131-140. PMID: 18932017, DOI: 10.1007/s10549-008-0219-7.Peer-Reviewed Original ResearchConceptsMiR-21 expressionPoor disease-free survivalHigh miR-21 expressionDisease-free survivalHormone receptor statusHigh miR-21Breast cancerMiR-21Tumor samplesReceptor statusTumor gradeTGF-β1Elevated miR-21 expressionNegative hormone receptor statusProportional hazards regression analysisHigher TGF-β1Lymph node involvementEarly-stage diseaseEarly-stage patientsPrimary breast cancerHazards regression analysisHigh tumor gradeFresh tumor samplesTumor cell growthNode involvement